Jelle Evers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jelle Evers has a total of 166 co-authors. Here are the top co-authors by number of shared publications:
- Sabine Siesling
Department of Health Technology and Services Research, Technical Medical Centre, University of Twente, Enschede, the Netherlands; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands
4 shared publications H. Struikmans
Department of Radiation Oncology, Leiden University Medical Centre, Leiden, The Netherlands
3 shared publicationsHenk Struikmans
Leiden University Medical Center, Department of Radiation Oncology, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
3 shared publicationsMieke J. Aarts
Netherlands Comprehensive Cancer Organisation (IKNL), Department of Research and Development, Godebaldkwartier 419, 3511 DT Utrecht, the Netherlands
3 shared publicationsSabine Siesling
Netherlands Comprehensive Cancer Organisation (IKNL), Department of Research and Development, Godebaldkwartier 419, 3511 DT Utrecht, the Netherlands; University of Twente, Department of Health Technology and Services Research, Technical Medical Center, Hallenweg 5, 7522 NH Enschede, the Netherlands
3 shared publications- Antonella Delmestri
University of Oxford
2 shared publications
Latest Publications
- 12 June 2026
- Published by Elsevier in Clinical Oncology
- Vol. 56, 104211
The Relevance of Cancer-Type-Specific Scenarios in Predicting Primary Radiotherapy Use in Nonmetastatic Cancer Patients in the Netherlands Towards 2032
- 12 June 2026
- Published by Elsevier in Clinical Oncology
- Vol. 56, 104211
The Relevance of Cancer-Type-Specific Scenarios in Predicting Primary Radiotherapy Use in Nonmetastatic Cancer Patients in the Netherlands Towards 2032
- Open Access
- 10 March 2026
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 65, 193-200
Characteristics, treatment and survival of patients with chondrosarcoma in five European countries: a DARWIN EU® cohort study
Background and purpose: Chondrosarcoma is a rare bone malignancy with a poor response to systemic therapy in advanced stages. European-level epidemiological data remain scarce. This study aimed to characterise patient demographics, treatments and survival using real-world data to inform regulatory decisions about the feasibility and design of new trials for the systemic treatment of chondrosarcoma. Patient/material and methods: This cohort study, part of the DARWIN EU® initiative, analysed data from six healthcare databases in Finland, France, the Netherlands, Spain and the UK. Patients diagnosed with chondrosarcoma between 2010 and 2022 were identified. Standardised analyses were performed within a federated network using the Observational Medical Outcomes Partnership (OMOP) Common Data Model. Results: A total of 2,498 chondrosarcoma patient records were identified, covering at least 2,356 unique patients. Median age at diagnosis was 52–55 years, with a balanced sex distribution. Surgical treatment was the most common intervention, recorded in 15.2% to 88.9% of patients, depending on the database. Fewer than 5% received systemic anticancer therapy, and radiotherapy was reported in fewer than 7%. The 10-year overall survival (OS) ranged from 58% (95% confidence interval [CI]: 43–78) to 80% (95% CI: 78–82), with restricted mean survival between 7.4 and 8.7 years. In the Netherlands, patients with late-stage, metastatic or high-grade disease showed significantly poorer outcomes. Interpretation: This study demonstrates the feasibility of using real-world data across Europe to describe chondrosarcoma patients. Most had early-stage, low-grade disease amenable to surgery, with limited use of systemic therapies. Survival was generally favourable, except in advanced disease. Clinical trials remain difficult due to the rarity of advanced chondrosarcoma and the lack of standards.
- 10 March 2026
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 65, 193-200
Open AccessCharacteristics, treatment and survival of patients with chondrosarcoma in five European countries: a DARWIN EU® cohort study
Background and purpose: Chondrosarcoma is a rare bone malignancy with a poor response to systemic therapy in advanced stages. European-level epidemiological data remain scarce. This study aimed to characterise patient demographics, treatments and survival using real-world data to inform regulatory decisions about the feasibility and design of new trials for the systemic treatment of chondrosarcoma. Patient/material and methods: This cohort study, part of the DARWIN EU® initiative, analysed data from six healthcare databases in Finland, France, the Netherlands, Spain and the UK. Patients diagnosed with chondrosarcoma between 2010 and 2022 were identified. Standardised analyses were performed within a federated network using the Observational Medical Outcomes Partnership (OMOP) Common Data Model. Results: A total of 2,498 chondrosarcoma patient records were identified, covering at least 2,356 unique patients. Median age at diagnosis was 52–55 years, with a balanced sex distribution. Surgical treatment was the most common intervention, recorded in 15.2% to 88.9% of patients, depending on the database. Fewer than 5% received systemic anticancer therapy, and radiotherapy was reported in fewer than 7%. The 10-year overall survival (OS) ranged from 58% (95% confidence interval [CI]: 43–78) to 80% (95% CI: 78–82), with restricted mean survival between 7.4 and 8.7 years. In the Netherlands, patients with late-stage, metastatic or high-grade disease showed significantly poorer outcomes. Interpretation: This study demonstrates the feasibility of using real-world data across Europe to describe chondrosarcoma patients. Most had early-stage, low-grade disease amenable to surgery, with limited use of systemic therapies. Survival was generally favourable, except in advanced disease. Clinical trials remain difficult due to the rarity of advanced chondrosarcoma and the lack of standards.
- 17 December 2024
- Published by Elsevier in Clinical Oncology
- Vol. 38, 103740
Deintensification of Radiotherapy Use in Treatment of Ductal Carcinoma In Situ in the Netherlands–A Nationwide Overview From 2008 Until 2022
- 17 December 2024
- Published by Elsevier in Clinical Oncology
- Vol. 38, 103740
Deintensification of Radiotherapy Use in Treatment of Ductal Carcinoma In Situ in the Netherlands–A Nationwide Overview From 2008 Until 2022
- Open Access
Trends of use of drugs with suggested shortages and their alternatives across 52 real world data sources and 18 countries in Europe and North America
Importance Drug production not meeting the demand leaves affected patients in a vulnerable position. Objective To describe incidence and prevalence of medicines with suggested shortages in at least one European country Design We performed a descriptive cohort study between 2010 in a network of databases which have mapped their data to the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM). Setting Setting included primary care, secondary care, and various disease registries whose previously collected data was leveraged. Participants We included all patients with at least 365 days of history on the database. Exposures We investigated all medicines with a suggested shortage in at least one European country for more than 365 days (n=18). Furthermore, we assessed their alternatives as well (n=39). Main outcomes and measures We estimated annual incidence rates and period prevalence of all medicines with suggested shortages and their alternatives. A drop in incidence or prevalence of more than 33% after the shortage announce by the European Medicines Agency was considered confirmation of a shortage. Results Among 41 databases from Europe and the United States, we observed shortages according to incidence for 12 drugs and shortages according to prevalence for 4 drugs. The drugs varenicline, cetrorelix, and amoxicillin plus clavulanate were in shortage in the most countries. Conclusion and relevance We compiled and analysed data of annual incidence and prevalence of 57 medicines among 41 databases in Europe and the United States. We detected shortages of several drugs and suggest monitoring and stewardship for drug availability.
Open AccessTrends of use of drugs with suggested shortages and their alternatives across 52 real world data sources and 18 countries in Europe and North America
Importance Drug production not meeting the demand leaves affected patients in a vulnerable position. Objective To describe incidence and prevalence of medicines with suggested shortages in at least one European country Design We performed a descriptive cohort study between 2010 in a network of databases which have mapped their data to the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM). Setting Setting included primary care, secondary care, and various disease registries whose previously collected data was leveraged. Participants We included all patients with at least 365 days of history on the database. Exposures We investigated all medicines with a suggested shortage in at least one European country for more than 365 days (n=18). Furthermore, we assessed their alternatives as well (n=39). Main outcomes and measures We estimated annual incidence rates and period prevalence of all medicines with suggested shortages and their alternatives. A drop in incidence or prevalence of more than 33% after the shortage announce by the European Medicines Agency was considered confirmation of a shortage. Results Among 41 databases from Europe and the United States, we observed shortages according to incidence for 12 drugs and shortages according to prevalence for 4 drugs. The drugs varenicline, cetrorelix, and amoxicillin plus clavulanate were in shortage in the most countries. Conclusion and relevance We compiled and analysed data of annual incidence and prevalence of 57 medicines among 41 databases in Europe and the United States. We detected shortages of several drugs and suggest monitoring and stewardship for drug availability.
- 22 August 2024
- Published by Elsevier in Clinical Oncology
- Vol. 36 (12) , 765-779
Radiotherapy Trends and Variations in Invasive Non-metastatic Breast Cancer Treatment in the Netherlands: A Nationwide Overview From 2008 to 2019
- 22 August 2024
- Published by Elsevier in Clinical Oncology
- Vol. 36 (12) , 765-779
Radiotherapy Trends and Variations in Invasive Non-metastatic Breast Cancer Treatment in the Netherlands: A Nationwide Overview From 2008 to 2019
- Open Access
- 31 October 2022
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 177, 134-142
Trends and variation in the use of radiotherapy in non-metastatic prostate cancer: A 12-year nationwide overview from the Netherlands
- 31 October 2022
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 177, 134-142
Open AccessTrends and variation in the use of radiotherapy in non-metastatic prostate cancer: A 12-year nationwide overview from the Netherlands
- Open Access
- 1 December 2021
- Published by Elsevier in Lung Cancer
- Vol. 162, 61-70
Trends and variations in the treatment of stage I-III small cell lung cancer from 2008 to 2019: A nationwide population-based study from the Netherlands
- 1 December 2021
- Published by Elsevier in Lung Cancer
- Vol. 162, 61-70
Open AccessTrends and variations in the treatment of stage I-III small cell lung cancer from 2008 to 2019: A nationwide population-based study from the Netherlands
- Open Access
- 1 May 2021
- Published by Elsevier in Lung Cancer
- Vol. 155, 103-113
Trends and variations in treatment of stage I–III non-small cell lung cancer from 2008 to 2018: A nationwide population-based study from the Netherlands
- 1 May 2021
- Published by Elsevier in Lung Cancer
- Vol. 155, 103-113
Open AccessTrends and variations in treatment of stage I–III non-small cell lung cancer from 2008 to 2018: A nationwide population-based study from the Netherlands